Zacks Investment Research downgraded shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
CLBS has been the subject of a number of other research reports. ValuEngine upgraded shares of Caladrius Biosciences from a strong sell rating to a sell rating in a research note on Friday, September 1st. HC Wainwright restated a buy rating and set a $7.00 price target on shares of Caladrius Biosciences in a research note on Friday, July 21st.
Caladrius Biosciences (CLBS) opened at 3.67 on Wednesday. The stock’s 50 day moving average price is $3.81 and its 200 day moving average price is $4.34. Caladrius Biosciences has a 12-month low of $2.65 and a 12-month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.08. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 180.68%. On average, analysts predict that Caladrius Biosciences will post ($2.42) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Caladrius Biosciences by 2.8% during the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock worth $723,000 after buying an additional 4,163 shares in the last quarter. KCG Holdings Inc. increased its holdings in shares of Caladrius Biosciences by 74.6% during the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock worth $183,000 after buying an additional 15,501 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Caladrius Biosciences by 34.3% during the first quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock worth $491,000 after buying an additional 24,900 shares in the last quarter. 6.47% of the stock is owned by institutional investors.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com